Second quarter (2022-10-01 - 2022-12-31)
The Group's net sales amounted to
The Group's loss after financial items amounted to
Result per share amounted to
Six months (2022-07-01 - 2022-12-31)
The Group's net sales amounted to
The Group's loss after financial items amounted to
Result per share amounted to
The solidity as of 2022-12-31 was 81% (93%).**
* The Company's result per share: The result for the period divided by the number of shares at the end of the period. The total number of shares as of 31st of
** Solidity: Equity divided by total capital.
Highlights during Q2
December -
Highlights after the end of the period
January -
Comments by CEO
I am delighted to say that we have started the new year with an important step forward with Project Poland. With our Marketing Authorization Holder application now approved, we can continue to work on getting all the necessary transit permits in place to begin our operations on the Polish market.
As we have previously communicated, we have been working for the past two years to get our Marketing Authorization Holder application approved, it is therefore extremely gratifying that we have now received it and that we are now in a position where we have the right to carry out medical cannabis operations and upcoming business activities on the Polish market.
We have an already established cooperation with one of the leading pharmaceutical wholesales in
While much of our work is being put into Project Poland as it is our main focus, we continue to work on establishing our CBD-infused skincare brand kandol. on the European market under Project Skin. It is clear that the interest in cannabinoids in cosmetics is high and it is therefore important that we ensure that kandol. can be offered to the market through our collaborations with European retailers, skin clinics, pharmaceutical distribution platforms and online partners. We are also working to strengthen our social media presence to reach out to potential customers.
Finally, I would like to thank our shareholders who continue to follow our journey towards becoming a European leader in the pharmaceutical market for offering medical cannabis products and CBD-infused skin care products. Together, we now look forward to the development we have ahead of us in the second half of the financial year.
For more information on
Derek Simmross, CEO,
E-mail: info@odipharma.com
https://news.cision.com/odi-pharma/r/odi-pharma-ab--publication-of-half-year-report-2022-2023,c3722726
https://mb.cision.com/Main/19043/3722726/1872841.pdf
(c) 2023 Cision. All rights reserved., source